Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Glanbia is an Irish-domiciled global nutrition company operating two primary divisions: Glanbia Performance Nutrition (GPN), which manufactures and markets sports nutrition brands including Optimum Nutrition, BSN, and Isopure across 130+ countries, and Glanbia Nutritionals (GN), which produces functional ingredients like whey protein, cheese, and dairy-based nutritional solutions for food manufacturers. The company's competitive position centers on vertical integration from dairy sourcing through branded consumer products, with significant manufacturing footprint in the US (Idaho, Wisconsin) and Ireland, though recent sharp revenue and earnings declines suggest portfolio restructuring or divestiture activity.
GPN generates margins through brand equity and innovation in sports nutrition (Optimum Nutrition commands premium pricing with 25-30% retail market share in protein powder category), leveraging direct-to-consumer e-commerce (higher margins) alongside traditional retail distribution. GN monetizes dairy processing scale and technical expertise, converting commodity milk into high-value functional ingredients with 15-20% EBITDA margins through long-term supply contracts with food manufacturers. Vertical integration from dairy procurement through finished goods provides cost advantages, though commodity milk and whey pricing creates margin volatility. The 29% revenue decline suggests significant business unit divestiture or portfolio rationalization occurred in recent periods.
GPN volume growth and market share trends in key categories (protein powder, ready-to-drink shakes) across North America and international markets, particularly e-commerce penetration rates
Whey protein commodity pricing and dairy input costs - spot whey protein concentrate (WPC80) pricing directly impacts GN margins with 3-6 month lag on contracted volumes
US dollar strength against euro and other currencies - estimated 40-50% of revenue outside US creates FX translation headwinds when dollar strengthens
M&A activity and portfolio optimization - company has history of bolt-on acquisitions in sports nutrition and potential for further business unit divestitures given recent revenue contraction
Retail inventory destocking cycles in sports nutrition channel - distributor/retailer inventory levels create quarterly volume volatility
Regulatory scrutiny of sports nutrition claims and ingredient safety - FDA oversight of dietary supplements could increase compliance costs or restrict product formulations, particularly for pre-workout and weight management categories
Shift toward whole-food protein sources and plant-based alternatives - consumer preference migration from whey-based supplements to pea/rice protein or animal-based whole foods (Greek yogurt, eggs) threatens long-term category growth
Private label penetration in protein powder category - retailer-owned brands at 30-40% price discounts eroding branded market share in mass channel
Intense competition from Nestle Health Science (Garden of Life, Nuun), Post Holdings (Premier Protein), and emerging DTC brands (Transparent Labs, Legion Athletics) with lower customer acquisition costs
Amazon's private label expansion in sports nutrition (Solimo protein powder) and algorithmic suppression of branded search results reducing GPN's e-commerce profitability
Commodity whey protein suppliers forward-integrating into branded products, leveraging cost advantages to undercut GPN pricing
Pension obligations in Ireland and UK operations - estimated €150-200M underfunded pension liabilities create cash funding requirements and balance sheet volatility from discount rate changes
Goodwill and intangible assets from historical acquisitions (Optimum Nutrition, BSN, Isopure) subject to impairment risk if sports nutrition category growth decelerates below 3-5% CAGR assumptions
Working capital intensity during dairy commodity price spikes - rising milk costs require increased inventory financing, straining cash flow during Q2-Q3 peak production periods
moderate - GPN sports nutrition products show resilience during mild recessions as fitness enthusiasts maintain supplement purchases, but premium product mix shifts to value brands during severe downturns. GN ingredient sales correlate with food/beverage manufacturing activity and consumer packaged goods production volumes, creating moderate GDP sensitivity. Consumer discretionary spending on fitness/wellness and protein-fortified foods drives 60-70% of end demand.
Rising rates moderately impact valuation multiples as consumer staples trade at premium P/E ratios that compress when risk-free rates increase. Debt service costs are manageable with 0.51x debt/equity ratio and estimated $250-300M net debt, suggesting minimal earnings impact from 100-200bps rate moves. Higher rates may reduce M&A activity and private label competition from private equity-backed brands in sports nutrition category.
Minimal direct credit exposure. Company operates with investment-grade credit profile and generates positive free cash flow. Indirect exposure through retail channel partners (specialty nutrition retailers, mass merchants) where customer bankruptcies could create receivables risk, though diversified customer base limits concentration.
value - Current 1.2x price/sales and 2.5x price/book ratios below historical averages (1.5-1.8x P/S, 3.0-3.5x P/B) attract value investors seeking recovery from recent restructuring. 7.3% FCF yield appeals to cash flow-focused investors. Dividend yield likely in 2-3% range supports income-oriented European institutional holders. Recent 36% one-year return suggests momentum investors entering on turnaround thesis, though -47% net income decline creates earnings quality concerns.
moderate - Consumer staples classification provides defensive characteristics, but sports nutrition exposure and commodity input volatility create earnings variability. Estimated beta 0.8-1.0 relative to broader market. FX translation from euro reporting and dollar-denominated operations adds 5-10% revenue volatility. Thinly traded ADRs in US market may exhibit higher intraday volatility than underlying Irish-listed shares.
